[FG] Kuhle Jens
Publications
691 found
Show per page
Dargvainiene, Justina et al. (2026) ‘Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients’, Clinical Chemistry and Laboratory Medicine, 64. Available at: https://doi.org/10.1515/cclm-2025-1476.
Dargvainiene, Justina et al. (2026) ‘Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients’, Clinical Chemistry and Laboratory Medicine, 64. Available at: https://doi.org/10.1515/cclm-2025-1476.
Gomes, N.V. et al. (2026) ‘PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery – protocol for an international, multicentre, prospective cohort study’, BMJ Open, 16(3), p. e115288. Available at: https://doi.org/10.1136/bmjopen-2025-115288.
Gomes, N.V. et al. (2026) ‘PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery – protocol for an international, multicentre, prospective cohort study’, BMJ Open, 16(3), p. e115288. Available at: https://doi.org/10.1136/bmjopen-2025-115288.
Sandgren, S. et al. (2026) ‘Are neurofilament light chain levels ready for routine clinical use? – Yes’, Multiple Sclerosis Journal [Preprint]. Available at: https://doi.org/10.1177/13524585261423032.
Sandgren, S. et al. (2026) ‘Are neurofilament light chain levels ready for routine clinical use? – Yes’, Multiple Sclerosis Journal [Preprint]. Available at: https://doi.org/10.1177/13524585261423032.
de Natale, E.R. et al. (2026) ‘In Vivo Mapping of Catecholaminergic Loss and Iron Deposition in Huntington’s Disease’, Movement Disorders [Preprint]. Available at: https://doi.org/10.1002/mds.70221.
de Natale, E.R. et al. (2026) ‘In Vivo Mapping of Catecholaminergic Loss and Iron Deposition in Huntington’s Disease’, Movement Disorders [Preprint]. Available at: https://doi.org/10.1002/mds.70221.
Kana, V. et al. (2026) ‘Use of optical coherence tomography in the care of people with multiple sclerosis in Switzerland: A national survey among neurologists’, Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(1). Available at: https://doi.org/10.1177/20552173261419951.
Kana, V. et al. (2026) ‘Use of optical coherence tomography in the care of people with multiple sclerosis in Switzerland: A national survey among neurologists’, Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(1). Available at: https://doi.org/10.1177/20552173261419951.
Kessler, Christoph et al. (2026) ‘Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4’, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 27. Available at: https://doi.org/10.1080/21678421.2025.2557936.
Kessler, Christoph et al. (2026) ‘Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4’, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 27. Available at: https://doi.org/10.1080/21678421.2025.2557936.
Lizak, Nathaniel et al. (2026) ‘Managing reactivation of multiple sclerosis during treatment with natalizumab’, Multiple Sclerosis Journal, 32, pp. 121–133. Available at: https://doi.org/10.1177/13524585251398682.
Lizak, Nathaniel et al. (2026) ‘Managing reactivation of multiple sclerosis during treatment with natalizumab’, Multiple Sclerosis Journal, 32, pp. 121–133. Available at: https://doi.org/10.1177/13524585251398682.
Chitnis, Tanuja et al. (2025) ‘Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications’, Lancet Neurology, 24, pp. 1066–1078. Available at: https://doi.org/10.1016/s1474-4422(25)00249-2.
Chitnis, Tanuja et al. (2025) ‘Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications’, Lancet Neurology, 24, pp. 1066–1078. Available at: https://doi.org/10.1016/s1474-4422(25)00249-2.
Delaby, Constance et al. (2025) ‘Biomarkers’, Alzheimer S Dementia the Journal of the Alzheimer S Association, 21, p. e104274. Available at: https://doi.org/10.1002/alz70856_104274.
Delaby, Constance et al. (2025) ‘Biomarkers’, Alzheimer S Dementia the Journal of the Alzheimer S Association, 21, p. e104274. Available at: https://doi.org/10.1002/alz70856_104274.
Iaquinto, Stefania et al. (2025) ‘From diagnosis to treatment: patterns in disease-modifying therapy initiation in multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251398472.
Iaquinto, Stefania et al. (2025) ‘From diagnosis to treatment: patterns in disease-modifying therapy initiation in multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251398472.
Pirmani, Ashkan et al. (2025) ‘Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data’, Npj Digital Medicine, 8. Available at: https://doi.org/10.1038/s41746-025-01788-8.
Pirmani, Ashkan et al. (2025) ‘Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data’, Npj Digital Medicine, 8. Available at: https://doi.org/10.1038/s41746-025-01788-8.
Maceski, Aleksandra Maleska et al. (2025) ‘GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf433.
Maceski, Aleksandra Maleska et al. (2025) ‘GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf433.
Engelter, Stefan T. et al. (2025) ‘Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial’, JAMA, 334, pp. 1523–1532. Available at: https://doi.org/10.1001/jama.2025.15185.
Engelter, Stefan T. et al. (2025) ‘Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial’, JAMA, 334, pp. 1523–1532. Available at: https://doi.org/10.1001/jama.2025.15185.
Abdelhak, Ahmed et al. (2025) ‘Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis’, Journal of Neurology Neurosurgery and Psychiatry, 96, pp. 1046–1052. Available at: https://doi.org/10.1136/jnnp-2025-335831.
Abdelhak, Ahmed et al. (2025) ‘Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis’, Journal of Neurology Neurosurgery and Psychiatry, 96, pp. 1046–1052. Available at: https://doi.org/10.1136/jnnp-2025-335831.
Baumgartner, Tobias et al. (2025) ‘Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis: Long-Term Outcome in 236 Patients’, Neurology R Neuroimmunology Neuroinflammation, 12, p. e200469. Available at: https://doi.org/10.1212/nxi.0000000000200469.
Baumgartner, Tobias et al. (2025) ‘Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis: Long-Term Outcome in 236 Patients’, Neurology R Neuroimmunology Neuroinflammation, 12, p. e200469. Available at: https://doi.org/10.1212/nxi.0000000000200469.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12, pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12, pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12(11), pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12(11), pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI ‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12(11), pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI ‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12(11), pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Klyscz, Philipp et al. (2025) ‘Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non-Optic Neuritis Onset’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70375.
Klyscz, Philipp et al. (2025) ‘Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non-Optic Neuritis Onset’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70375.
Riboni-Verri, Gioia et al. (2025) ‘Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis’, Multiple Sclerosis and Related Disorders, 103. Available at: https://doi.org/10.1016/j.msard.2025.106655.
Riboni-Verri, Gioia et al. (2025) ‘Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis’, Multiple Sclerosis and Related Disorders, 103. Available at: https://doi.org/10.1016/j.msard.2025.106655.
Sandgren, Sofia et al. (2025) ‘Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity’, Multiple Sclerosis Journal, 31, pp. 1531–1542. Available at: https://doi.org/10.1177/13524585251375780.
Sandgren, Sofia et al. (2025) ‘Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity’, Multiple Sclerosis Journal, 31, pp. 1531–1542. Available at: https://doi.org/10.1177/13524585251375780.
Sandgren, Sofia et al. (2025) ‘Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity’, Multiple Sclerosis Journal, 31(13), pp. 1531–1542. Available at: https://doi.org/10.1177/13524585251375780.
Sandgren, Sofia et al. (2025) ‘Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity’, Multiple Sclerosis Journal, 31(13), pp. 1531–1542. Available at: https://doi.org/10.1177/13524585251375780.
Bochud, M. et al. (2025) ‘Cohort Profile: Swiss Personalized Health Network Cohort Consortium’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2025.10.10.25337504.
Bochud, M. et al. (2025) ‘Cohort Profile: Swiss Personalized Health Network Cohort Consortium’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2025.10.10.25337504.
Fillebeen, G. et al. (2025) ‘Investigating neuroanatomical correlates of neuropathic pain in multiple sclerosis: A pilot comparative study using advanced MRI techniques’, Revue Neurologique, 181, pp. 765–774. Available at: https://doi.org/10.1016/j.neurol.2025.06.011.
Fillebeen, G. et al. (2025) ‘Investigating neuroanatomical correlates of neuropathic pain in multiple sclerosis: A pilot comparative study using advanced MRI techniques’, Revue Neurologique, 181, pp. 765–774. Available at: https://doi.org/10.1016/j.neurol.2025.06.011.
Rebeaud, Jessica et al. (2025) ‘Blood metabolomics improves prediction of central nervous system damage in multiple sclerosis’, Metabolomics, 21. Available at: https://doi.org/10.1007/s11306-025-02315-2.
Rebeaud, Jessica et al. (2025) ‘Blood metabolomics improves prediction of central nervous system damage in multiple sclerosis’, Metabolomics, 21. Available at: https://doi.org/10.1007/s11306-025-02315-2.
Furlan, Roberto et al. (2025) ‘Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf345.
Furlan, Roberto et al. (2025) ‘Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf345.
Booth, Ronald A. et al. (2025) ‘Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay’, Clinica Chimica Acta, 577. Available at: https://doi.org/10.1016/j.cca.2025.120447.
Booth, Ronald A. et al. (2025) ‘Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay’, Clinica Chimica Acta, 577. Available at: https://doi.org/10.1016/j.cca.2025.120447.
Chen, Xinjie et al. (2025) ‘Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/NXI.0000000000200459.
Chen, Xinjie et al. (2025) ‘Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/NXI.0000000000200459.
Chen, Xinjie et al. (2025) ‘Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(5). Available at: https://doi.org/10.1212/nxi.0000000000200459.
Chen, Xinjie et al. (2025) ‘Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(5). Available at: https://doi.org/10.1212/nxi.0000000000200459.
Cortese, Marianna et al. (2025) ‘Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression’, Neurology, 105. Available at: https://doi.org/10.1212/wnl.0000000000213905.
Cortese, Marianna et al. (2025) ‘Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression’, Neurology, 105. Available at: https://doi.org/10.1212/wnl.0000000000213905.
Abdelhak, Ahmed et al. (2025) ‘Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination’, Brain, 148, pp. 3011–3020. Available at: https://doi.org/10.1093/brain/awaf144.
Abdelhak, Ahmed et al. (2025) ‘Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination’, Brain, 148, pp. 3011–3020. Available at: https://doi.org/10.1093/brain/awaf144.
Cagol, Alessandro et al. (2025) ‘Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13221-x.
Cagol, Alessandro et al. (2025) ‘Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13221-x.
Cagol, Alessandro et al. (2025) ‘Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort’, Journal of Neurology, 272(8). Available at: https://doi.org/10.1007/s00415-025-13221-x.
Cagol, Alessandro et al. (2025) ‘Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort’, Journal of Neurology, 272(8). Available at: https://doi.org/10.1007/s00415-025-13221-x.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum’, Neurology Clinical Practice, 15(4). Available at: https://doi.org/10.1212/cpj.0000000000200499.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum’, Neurology Clinical Practice, 15(4). Available at: https://doi.org/10.1212/cpj.0000000000200499.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum Real-World Data From the Swiss Multiple Sclerosis Cohort’, Neurology Clinical Practice, 15. Available at: https://doi.org/10.1212/CPJ.0000000000200499.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum Real-World Data From the Swiss Multiple Sclerosis Cohort’, Neurology Clinical Practice, 15. Available at: https://doi.org/10.1212/CPJ.0000000000200499.
Burguet Villena, Federico et al. (2025) ‘Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13185-y.
Burguet Villena, Federico et al. (2025) ‘Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13185-y.
Burguet Villena, Federico et al. (2025) ‘Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis’, Journal of Neurology, 272(7). Available at: https://doi.org/10.1007/s00415-025-13185-y.
Burguet Villena, Federico et al. (2025) ‘Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis’, Journal of Neurology, 272(7). Available at: https://doi.org/10.1007/s00415-025-13185-y.
Fissolo, Nicolás et al. (2025) ‘Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome’, JAMA Neurology, 82. Available at: https://doi.org/10.1001/jamaneurol.2025.1481.
Fissolo, Nicolás et al. (2025) ‘Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome’, JAMA Neurology, 82. Available at: https://doi.org/10.1001/jamaneurol.2025.1481.
Klimas, Rafael et al. (2025) ‘Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/nxi.0000000000200419.
Klimas, Rafael et al. (2025) ‘Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/nxi.0000000000200419.
Kuhlmann, Jenni et al. (2025) ‘Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial’, Multiple Sclerosis Journal Experimental Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251352712.
Kuhlmann, Jenni et al. (2025) ‘Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial’, Multiple Sclerosis Journal Experimental Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251352712.
Kuhlmann, Jenni et al. (2025) ‘Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial’, Multiple Sclerosis Journal - Experimental Translational and Clinical, (3), p. 20552173251352712. Available at: https://doi.org/10.1177/20552173251352712.
Kuhlmann, Jenni et al. (2025) ‘Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial’, Multiple Sclerosis Journal - Experimental Translational and Clinical, (3), p. 20552173251352712. Available at: https://doi.org/10.1177/20552173251352712.
Yaldizli, Özgür et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Multiple Sclerosis Journal, 31, pp. 932–943. Available at: https://doi.org/10.1177/13524585251335466.
Yaldizli, Özgür et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Multiple Sclerosis Journal, 31, pp. 932–943. Available at: https://doi.org/10.1177/13524585251335466.
Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.
Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.
Delaby, Constance et al. (2025) ‘Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview’, Alzheimer S and Dementia, 21. Available at: https://doi.org/10.1002/alz.70343.
Delaby, Constance et al. (2025) ‘Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview’, Alzheimer S and Dementia, 21. Available at: https://doi.org/10.1002/alz.70343.
Iaquinto, Stefania et al. (2025) ‘Confirmed Worsening of Health-Related Quality of Life to Monitor Long-Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70230.
Iaquinto, Stefania et al. (2025) ‘Confirmed Worsening of Health-Related Quality of Life to Monitor Long-Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70230.
Lorscheider, Johannes et al. (2025) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: Results from the Big MS Data Network’, Journal of Neurology Neurosurgery and Psychiatry, 96, pp. 606–615. Available at: https://doi.org/10.1136/jnnp-2024-334700.
Lorscheider, Johannes et al. (2025) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: Results from the Big MS Data Network’, Journal of Neurology Neurosurgery and Psychiatry, 96, pp. 606–615. Available at: https://doi.org/10.1136/jnnp-2024-334700.
Greselin, Martina et al. (2025) ‘AI-assisted identification of disability patterns within identical EDSS grades’, Multiple Sclerosis Journal, 31(6), pp. 677–688. Available at: https://doi.org/10.1177/13524585251327300.
Greselin, Martina et al. (2025) ‘AI-assisted identification of disability patterns within identical EDSS grades’, Multiple Sclerosis Journal, 31(6), pp. 677–688. Available at: https://doi.org/10.1177/13524585251327300.
Lim Falk, V. et al. (2025) ‘Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(4). Available at: https://doi.org/10.1212/nxi.0000000000200404.
Lim Falk, V. et al. (2025) ‘Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(4). Available at: https://doi.org/10.1212/nxi.0000000000200404.
Ocampo-Pineda, Mario et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/NXI.0000000000200388.
Ocampo-Pineda, Mario et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/NXI.0000000000200388.
Radford-Smith, Daniel E. et al. (2025) ‘Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis’, BMJ Neurology Open, 7. Available at: https://doi.org/10.1136/bmjno-2025-001026.
Radford-Smith, Daniel E. et al. (2025) ‘Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis’, BMJ Neurology Open, 7. Available at: https://doi.org/10.1136/bmjno-2025-001026.
Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.
Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.
Rossini, Fabio et al. (2025) ‘Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers’, International Journal of Molecular Sciences, 26. Available at: https://doi.org/10.3390/ijms26062629.
Rossini, Fabio et al. (2025) ‘Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers’, International Journal of Molecular Sciences, 26. Available at: https://doi.org/10.3390/ijms26062629.
Schiess, C. et al. (2025) ‘Prevalence, risk factors and impact of delirium in adult inpatients in a tertiary care hospital: A point prevalence study’, Journal of Clinical Nursing, 34(3), pp. 921–931. Available at: https://doi.org/10.1111/jocn.17113.
Schiess, C. et al. (2025) ‘Prevalence, risk factors and impact of delirium in adult inpatients in a tertiary care hospital: A point prevalence study’, Journal of Clinical Nursing, 34(3), pp. 921–931. Available at: https://doi.org/10.1111/jocn.17113.
Mondesert, E. et al. (2025) ‘Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis’, Neurology, 104(6). Available at: https://doi.org/10.1212/wnl.0000000000213400.
Mondesert, E. et al. (2025) ‘Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis’, Neurology, 104(6). Available at: https://doi.org/10.1212/wnl.0000000000213400.
Gesierich, Benno et al. (2025) ‘Extended Technical and Clinical Validation of Deep Learning-Based Brainstem Segmentation for Application in Neurodegenerative Diseases’, Human Brain Mapping, 46. Available at: https://doi.org/10.1002/hbm.70141.
Gesierich, Benno et al. (2025) ‘Extended Technical and Clinical Validation of Deep Learning-Based Brainstem Segmentation for Application in Neurodegenerative Diseases’, Human Brain Mapping, 46. Available at: https://doi.org/10.1002/hbm.70141.
Dahl, Johannes Raffael et al. (2025) ‘Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/nxi.0000000000200374.
Dahl, Johannes Raffael et al. (2025) ‘Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/nxi.0000000000200374.
Dahl, Johannes Raffael et al. (2025) ‘Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200374.
Dahl, Johannes Raffael et al. (2025) ‘Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200374.
Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.
Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.
Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.
Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.
Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology. 16.10.2024, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.
Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology. 16.10.2024, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.
Bosticardo, Sara et al. (2025) ‘TIME: Tractography-Informed myelin estimation’, Neuroimage Clinical, 48. Available at: https://doi.org/10.1016/j.nicl.2025.103878.
Bosticardo, Sara et al. (2025) ‘TIME: Tractography-Informed myelin estimation’, Neuroimage Clinical, 48. Available at: https://doi.org/10.1016/j.nicl.2025.103878.
Disanto, Giulio et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251315457.
Disanto, Giulio et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251315457.
Disanto, Giulio et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 11(1). Available at: https://doi.org/10.1177/20552173251315457.
Disanto, Giulio et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 11(1). Available at: https://doi.org/10.1177/20552173251315457.
Foong, Yi Chao et al. (2025) ‘Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis’, Journal of Neurology Neurosurgery and Psychiatry [Preprint]. Available at: https://doi.org/10.1136/jnnp-2025-336513.
Foong, Yi Chao et al. (2025) ‘Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis’, Journal of Neurology Neurosurgery and Psychiatry [Preprint]. Available at: https://doi.org/10.1136/jnnp-2025-336513.
Hema Prashaad, M. et al. (2025) ‘Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies, pro-inflammatory cytokines, NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study’, Therapeutic Advances in Infectious Disease, 12. Available at: https://doi.org/10.1177/20499361251370471.
Hema Prashaad, M. et al. (2025) ‘Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies, pro-inflammatory cytokines, NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study’, Therapeutic Advances in Infectious Disease, 12. Available at: https://doi.org/10.1177/20499361251370471.
Herrera-Rivero, Marisol et al. (2025) ‘Utility of blood DNA methylation and immune cell-type estimates to identify clinically relevant links between immunity and health conditions in a large cohort’, Frontiers in Immunology, 16. Available at: https://doi.org/10.3389/fimmu.2025.1613557.
Herrera-Rivero, Marisol et al. (2025) ‘Utility of blood DNA methylation and immune cell-type estimates to identify clinically relevant links between immunity and health conditions in a large cohort’, Frontiers in Immunology, 16. Available at: https://doi.org/10.3389/fimmu.2025.1613557.
Konen, Franz Felix et al. (2025) ‘Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort’, Neurotherapeutics [Preprint]. Available at: https://doi.org/10.1016/j.neurot.2025.e00812.
Konen, Franz Felix et al. (2025) ‘Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort’, Neurotherapeutics [Preprint]. Available at: https://doi.org/10.1016/j.neurot.2025.e00812.
Laaksonen, Sini et al. (2025) ‘Predictors of risk of secondary progression in multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251357276.
Laaksonen, Sini et al. (2025) ‘Predictors of risk of secondary progression in multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251357276.
Nagy, Sara et al. (2025) ‘Automated analysis of quantitative muscle MRI and its reliability in patients with Duchenne muscular dystrophy’, Journal of Neuromuscular Diseases [Preprint]. 24.03.2025. Available at: https://doi.org/10.1177/22143602251319184.
Nagy, Sara et al. (2025) ‘Automated analysis of quantitative muscle MRI and its reliability in patients with Duchenne muscular dystrophy’, Journal of Neuromuscular Diseases [Preprint]. 24.03.2025. Available at: https://doi.org/10.1177/22143602251319184.
Sanabria-Diaz, Gretel et al. (2025) ‘Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis’, Annals of Neurology, 97, pp. 134–148. Available at: https://doi.org/10.1002/ana.27102.
Sanabria-Diaz, Gretel et al. (2025) ‘Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis’, Annals of Neurology, 97, pp. 134–148. Available at: https://doi.org/10.1002/ana.27102.
Schindler, Patrick et al. (2025) ‘Investigation of the association of serum GFAP and NfL with brain and upper cervical MRI volumes in AQP4-IgG-positive NMOSD and MOGAD’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251345792.
Schindler, Patrick et al. (2025) ‘Investigation of the association of serum GFAP and NfL with brain and upper cervical MRI volumes in AQP4-IgG-positive NMOSD and MOGAD’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251345792.
Sjöros, T. et al. (2025) ‘Serum glial fibrillary acid protein associates with TSPO-expressing lesions in multiple sclerosis brain’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251352998.
Sjöros, T. et al. (2025) ‘Serum glial fibrillary acid protein associates with TSPO-expressing lesions in multiple sclerosis brain’, Therapeutic Advances in Neurological Disorders, 18. Available at: https://doi.org/10.1177/17562864251352998.
Willemse, Eline A.J. et al. (2025) ‘Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls’, Clinical Chemistry and Laboratory Medicine [Preprint]. Available at: https://doi.org/10.1515/cclm-2025-1480.
Willemse, Eline A.J. et al. (2025) ‘Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls’, Clinical Chemistry and Laboratory Medicine [Preprint]. Available at: https://doi.org/10.1515/cclm-2025-1480.
Zhu, C. et al. (2025) ‘Persistent progression independent of relapse activity in multiple sclerosis’, Brain Communications, 7. Available at: https://doi.org/10.1093/braincomms/fcaf306.
Zhu, C. et al. (2025) ‘Persistent progression independent of relapse activity in multiple sclerosis’, Brain Communications, 7. Available at: https://doi.org/10.1093/braincomms/fcaf306.
Gomes, Ana Beatriz Ayroza Galvão Ribeiro et al. (2024) ‘Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/nxi.0000000000200347.
Gomes, Ana Beatriz Ayroza Galvão Ribeiro et al. (2024) ‘Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease’, Neurology Neuroimmunology and Neuroinflammation, 12. Available at: https://doi.org/10.1212/nxi.0000000000200347.
Fischer, Stefanie et al. (2024) ‘Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation’, Scientific Reports, 14. Available at: https://doi.org/10.1038/s41598-024-71603-z.
Fischer, Stefanie et al. (2024) ‘Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation’, Scientific Reports, 14. Available at: https://doi.org/10.1038/s41598-024-71603-z.
Haag, Christina et al. (2024) ‘Natural language processing analysis of the theories of people with multiple sclerosis about causes of their disease’, Communications Medicine, 4. Available at: https://doi.org/10.1038/s43856-024-00546-3.
Haag, Christina et al. (2024) ‘Natural language processing analysis of the theories of people with multiple sclerosis about causes of their disease’, Communications Medicine, 4. Available at: https://doi.org/10.1038/s43856-024-00546-3.
Hallenberger, Tim Jonas et al. (2024) ‘Early minimally invasive image-guided endoscopic evacuation of intracerebral hemorrhage (EMINENT-ICH): a randomized controlled trial’, Trials, 25. Available at: https://doi.org/10.1186/s13063-024-08534-7.
Hallenberger, Tim Jonas et al. (2024) ‘Early minimally invasive image-guided endoscopic evacuation of intracerebral hemorrhage (EMINENT-ICH): a randomized controlled trial’, Trials, 25. Available at: https://doi.org/10.1186/s13063-024-08534-7.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.
Sacco, Rosaria et al. (2024) ‘De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study’, Multiple Sclerosis and Related Disorders, 92. Available at: https://doi.org/10.1016/j.msard.2024.106145.
Sacco, Rosaria et al. (2024) ‘De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study’, Multiple Sclerosis and Related Disorders, 92. Available at: https://doi.org/10.1016/j.msard.2024.106145.
Pontillo, Giuseppe et al. (2024) ‘Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap’, Neurology, 103. Available at: https://doi.org/10.1212/wnl.0000000000209976.
Pontillo, Giuseppe et al. (2024) ‘Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap’, Neurology, 103. Available at: https://doi.org/10.1212/wnl.0000000000209976.
Iaquinto, Stefania et al. (2024) ‘Factors associated with low health-related quality of life in persons with multiple sclerosis: A quantile-based segmentation approach’, Plos One, 19. Available at: https://doi.org/10.1371/journal.pone.0312486.
Iaquinto, Stefania et al. (2024) ‘Factors associated with low health-related quality of life in persons with multiple sclerosis: A quantile-based segmentation approach’, Plos One, 19. Available at: https://doi.org/10.1371/journal.pone.0312486.
Di Filippo, Massimiliano et al. (2024) ‘Fluid biomarkers in multiple sclerosis: from current to future applications’, Lancet Regional Health Europe, 44. Available at: https://doi.org/10.1016/j.lanepe.2024.101009.
Di Filippo, Massimiliano et al. (2024) ‘Fluid biomarkers in multiple sclerosis: from current to future applications’, Lancet Regional Health Europe, 44. Available at: https://doi.org/10.1016/j.lanepe.2024.101009.
Wellmann, Sven et al. (2024) ‘Neurofilament Light Chain as Biomarker in Encephalitis’, Journal of Clinical Medicine, 13. Available at: https://doi.org/10.3390/jcm13185416.
Wellmann, Sven et al. (2024) ‘Neurofilament Light Chain as Biomarker in Encephalitis’, Journal of Clinical Medicine, 13. Available at: https://doi.org/10.3390/jcm13185416.
Müller, Jannis et al. (2024) ‘Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions’, Neurology. 30.08.2024, 103(6). Available at: https://doi.org/10.1212/wnl.0000000000209604.
Müller, Jannis et al. (2024) ‘Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions’, Neurology. 30.08.2024, 103(6). Available at: https://doi.org/10.1212/wnl.0000000000209604.
Linnemann, Christoph et al. (2024) ‘NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: A large GENFI study’, Journal of Neurology, Neurosurgery and Psychiatry, 95(9), pp. 822–828. Available at: https://doi.org/10.1136/jnnp-2023-332464.
Linnemann, Christoph et al. (2024) ‘NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: A large GENFI study’, Journal of Neurology, Neurosurgery and Psychiatry, 95(9), pp. 822–828. Available at: https://doi.org/10.1136/jnnp-2023-332464.
Linnemann, Christoph et al. (2024) ‘NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: A large GENFI study’, Journal of Neurology, Neurosurgery and Psychiatry, 95(9), pp. 822–828. Available at: https://doi.org/10.1136/jnnp-2023-332464.
Linnemann, Christoph et al. (2024) ‘NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: A large GENFI study’, Journal of Neurology, Neurosurgery and Psychiatry, 95(9), pp. 822–828. Available at: https://doi.org/10.1136/jnnp-2023-332464.
Greselin, Martina et al. (2024) ‘Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort’, Bioengineering, 11. Available at: https://doi.org/10.3390/bioengineering11080858.
Greselin, Martina et al. (2024) ‘Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort’, Bioengineering, 11. Available at: https://doi.org/10.3390/bioengineering11080858.
Roos, I. et al. (2024) ‘Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal, 30(9), pp. 1163–1175. Available at: https://doi.org/10.1177/13524585241267211.
Roos, I. et al. (2024) ‘Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal, 30(9), pp. 1163–1175. Available at: https://doi.org/10.1177/13524585241267211.
Schindler, P. et al. (2024) ‘Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study’, Multiple Sclerosis and Related Disorders, 88. Available at: https://doi.org/10.1016/j.msard.2024.105729.
Schindler, P. et al. (2024) ‘Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study’, Multiple Sclerosis and Related Disorders, 88. Available at: https://doi.org/10.1016/j.msard.2024.105729.
Zivadinov, R. et al. (2024) ‘Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA–MS case-controlled study’, Journal of Neurology, 271(8), pp. 4949–4962. Available at: https://doi.org/10.1007/s00415-024-12420-2.
Zivadinov, R. et al. (2024) ‘Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA–MS case-controlled study’, Journal of Neurology, 271(8), pp. 4949–4962. Available at: https://doi.org/10.1007/s00415-024-12420-2.
Chalkou, Konstantina et al. (2024) ‘Combining randomized and non-randomized data to predict heterogeneous effects of competing treatments’, Research Synthesis Methods, 15(4), pp. 641–656. Available at: https://doi.org/10.1002/jrsm.1717.
Chalkou, Konstantina et al. (2024) ‘Combining randomized and non-randomized data to predict heterogeneous effects of competing treatments’, Research Synthesis Methods, 15(4), pp. 641–656. Available at: https://doi.org/10.1002/jrsm.1717.
Zuo, Michelle et al. (2024) ‘Erratum: Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation (JCI insight PII: e183445)’, JCI insight, 9(12). Available at: https://doi.org/10.1172/jci.insight.183445.
Zuo, Michelle et al. (2024) ‘Erratum: Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation (JCI insight PII: e183445)’, JCI insight, 9(12). Available at: https://doi.org/10.1172/jci.insight.183445.
Signori, Alessio et al. (2024) ‘Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: An application using data from the MSBase Registry’, Journal of Neurology, Neurosurgery and Psychiatry, 95(7), pp. 620–625. Available at: https://doi.org/10.1136/jnnp-2023-332603.
Signori, Alessio et al. (2024) ‘Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: An application using data from the MSBase Registry’, Journal of Neurology, Neurosurgery and Psychiatry, 95(7), pp. 620–625. Available at: https://doi.org/10.1136/jnnp-2023-332603.
Fischbach, F. et al. (2024) ‘CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis’, Med, 5(6), pp. 550–558.e2. Available at: https://doi.org/10.1016/j.medj.2024.03.002.
Fischbach, F. et al. (2024) ‘CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis’, Med, 5(6), pp. 550–558.e2. Available at: https://doi.org/10.1016/j.medj.2024.03.002.
Maatta, L.L. et al. (2024) ‘Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark’, Diabetes Care, 47(6), pp. 986–994. Available at: https://doi.org/10.2337/dc23-2208.
Maatta, L.L. et al. (2024) ‘Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark’, Diabetes Care, 47(6), pp. 986–994. Available at: https://doi.org/10.2337/dc23-2208.
Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20(5), pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.
Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20(5), pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.
Müller, Jannis et al. (2024) ‘Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis’, Brain and Behavior. 30.04.2024, 14(5). Available at: https://doi.org/10.1002/brb3.3498.
Müller, Jannis et al. (2024) ‘Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis’, Brain and Behavior. 30.04.2024, 14(5). Available at: https://doi.org/10.1002/brb3.3498.
Sharmin, S. et al. (2024) ‘Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries’, The Lancet Child and Adolescent Health, 8(5), pp. 348–357. Available at: https://doi.org/10.1016/s2352-4642(24)00047-6.
Sharmin, S. et al. (2024) ‘Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries’, The Lancet Child and Adolescent Health, 8(5), pp. 348–357. Available at: https://doi.org/10.1016/s2352-4642(24)00047-6.
Montalban, Xavier et al. (2024) ‘Efficacy and safety results after > 3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study’, Multiple Sclerosis Journal, 30(4-5), pp. 558–570. Available at: https://doi.org/10.1177/13524585241234783.
Montalban, Xavier et al. (2024) ‘Efficacy and safety results after > 3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study’, Multiple Sclerosis Journal, 30(4-5), pp. 558–570. Available at: https://doi.org/10.1177/13524585241234783.